YM158 (free base) is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of specific molecular targets involved in cancer cell proliferation and survival. Research suggests its utility in inhibiting pathways that contribute to tumor growth, making it a candidate for the development of anticancer drugs. Studies focus on its efficacy in preclinical models, particularly in targeting cancers that are resistant to conventional therapies. Its application extends to exploring its role in combination therapies, where it may enhance the effectiveness of existing treatments. Further research is ongoing to evaluate its safety, pharmacokinetics, and potential for clinical use in treating various cancer types.